Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
9.65
+0.28 (2.99%)
At close: Sep 18, 2026, 4:00 PM EDT
9.65
0.00 (0.00%)
Pre-market: Sep 21, 2026, 4:02 AM EDT
Evommune Revenue
Evommune had revenue of $10.00M in the twelve months ending June 30, 2026, up 233.33% year-over-year. In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+233.33%
P/S Ratio
35.02
Revenue / Employee
$208,333
Employees
48
Market Cap
350.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
EVMN News
- 5 days ago - Evommune Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 days ago - Evommune Slides: Corporate presentation - Filings
- 11 days ago - Evommune price target lowered to $23 from $28 at Clear Street - TheFly
- 11 days ago - Evommune price target lowered to $18 from $32 at Raymond James - TheFly
- 11 days ago - Evommune price target lowered to $22 from $28 at Leerink - TheFly
- 11 days ago - Evommune price target lowered to $21 from $29 at RBC Capital - TheFly
- 12 days ago - Evommune scraps eczema drug after trial miss, shares plunge - Reuters
- 12 days ago - Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints - TheFly